文献速递腹部技术与安全CT

结直肠癌肝转移CT形态学肿瘤反应评估的观察者间变异性

Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases.
PubMed 文献 · Radiol Imaging Cancer · 2022-01-01

基于CAIRO5随机对照试验的前瞻性影像研究纳入153例初始不可切除结直肠癌肝转移患者共306次CT,由3名放射科医师独立按既定标准评估形态学肿瘤反应,观察者间一致性为中等(形态学分组κ=0.53,形态学反应分类κ=0.54)。最佳形态学反应多见于接受贝伐珠单抗治疗者(P=.001)及RAS/BRAF突变者(P=.04),RECIST 1.1与形态学反应间未见关系证据(P=.61)。

要点

  • 形态学肿瘤反应评估观察者间一致性中等(κ=0.53与0.54),阅片差异需警惕。
  • 44%病例三读者判断不一致,其中4例为重大分歧。
  • 最佳形态学反应多见于贝伐珠单抗治疗者(P=.001)及RAS/BRAF突变者(P=.04)。

核心结论

  • 结直肠癌肝转移患者系统治疗后的形态学肿瘤反应评估存在相当大的观察者间变异性。

研究设计与样本

  • 前瞻性影像研究,纳入随机对照CAIRO5试验(NCT02162563)中初始不可切除、接受不同系统治疗方案的结直肠癌肝转移患者153例(中位年龄63岁,IQR 56-71;男性101例),共306次基线及首次随访CT,由3名放射科医师独立评估,另2名放射科医师评估分歧病例,以Fleiss κ计算观察者间一致性。

诊断标准与关键数值

  • 依据既往发表标准评估形态学肿瘤反应;三读者评估中86例(56%)一致、67例(44%)不一致(含4例重大分歧);形态学分组观察者间一致性κ=0.53(95%CI:0.48,0.58),形态学反应分类κ=0.54(95%CI:0.47,0.60);以多数读者评估确定最终形态学肿瘤反应。

临床应用与阅片要点

  • 作者基于多数读者评估确定最终形态学肿瘤反应,并分析其与基因突变状态、靶向治疗及RECIST 1.1测量的关系。

局限性

  • 原文未报告局限性;但作者在结论中指出形态学肿瘤反应评估存在相当大的观察者间变异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate interobserver variability in the morphologic tumor response assessment of colorectal liver metastases (CRLM) managed with systemic therapy and to assess the relation of morphologic response with gene mutation status, targeted therapy, and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 measurements. Materials and Methods Participants with initially unresectable CRLM receiving different systemic therapy regimens from the randomized, controlled CAIRO5 trial (NCT02162563) were included in this prospective imaging study. Three radiologists independently assessed morphologic tumor response on baseline and first follow-up CT scans according to previously published criteria. Two additional radiologists evaluated disagreement cases. Interobserver agreement was calculated by using Fleiss κ. On the basis of the majority of individual radiologic assessments, the final morphologic tumor response was determined. Finally, the relation of morphologic tumor response and clinical prognostic parameters was assessed. Results In total, 153 participants (median age, 63 years [IQR, 56-71]; 101 men) with 306 CT scans comprising 2192 CRLM were included. Morphologic assessment performed by the three radiologists yielded 86 (56%) agreement cases and 67 (44%) disagreement cases (including four major disagreement cases). Overall interobserver agreement between the panel radiologists on morphology groups and morphologic response categories was moderate (κ = 0.53, 95% CI: 0.48, 0.58 and κ = 0.54, 95% CI: 0.47, 0.60). Optimal morphologic response was particularly observed in patients treated with bevacizumab (P = .001) and in patients with RAS/BRAF mutation (P = .04). No evidence of a relationship between RECIST 1.1 and morphologic response was found (P = .61). Conclusion Morphologic tumor response assessment following systemic therapy in participants with CRLM demonstrated considerable interobserver variability. Keywords: Tumor Response, Observer Performance, CT, Liver, Metastases, Oncology, Abdomen/Gastrointestinal Clinical trial registration no. NCT02162563 Supplemental material is available for this article. © RSNA, 2022.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Wesdorp NJ, Kemna R, Bolhuis K, et al. Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases. Radiol Imaging Cancer. 2022. PMID: 35522139. doi:10.1148/rycan.210105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。